Safety Study of a Lyme Disease Vaccine in Healthy Children
A Phase 3, Randomized, Placebo-Controlled, Observer- Blinded Trial to Evaluate the Safety of a 6-Valent OspABased Lyme Disease Vaccine (VLA15) in Healthy Children 5 Through 17 Years of Age
Category & Conditions: Vaccine-related Conditions
Medicine: PF-07307405
ClinicalTrials.gov Identifier (NCT): NCT05634811
Protocol ID: C4601012
Open Plain Language Summary Result:
Click here